Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18290496 | 0.88 | CYP3A4 (0.47) | NR2E1CYP3A4ALDH1A1LMNAMAPT | |
| SCHEMBL1882019 | 0.88 | CYP3A4 (0.47) | NR2E1CYP3A4ALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL17583800 | 0.86 | CYP3A4 (0.46) | NR2E1CYP3A4ALDH1A1LMNAMAPT | |
| SCHEMBL15315529 | 0.85 | MAP3K5 (0.42) | CYP3A4ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL14092962 | 0.84 | CYP3A4 (0.41) | NR2E1CYP3A4ALDH1A1LMNAMAPT | |
| SCHEMBL18288736 | 0.82 | CYP3A4 (0.52) | CYP3A4LMNAMAPTMEN1CYP1A2 | |
| SCHEMBL872411 | 0.82 | LMNA (0.53) | CYP3A4LMNAMAPTMEN1CYP1A2 | |
| SCHEMBL588961 | 0.81 | NR2E1 (0.56) | NR2E1CYP3A4ALDH1A1LMNAMAPT | |
| SCHEMBL30242168 | 0.81 | NR2E1 (0.56) | NR2E1CYP3A4ALDH1A1LMNAMAPT | |
| SCHEMBL14117050 | 0.80 | ENPP2 (0.39) | NR2E1CYP3A4ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8586566-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8513270-B2 | Substituted heterocycles as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | NR2E1 1246/4885CYP3A4 73/4885ALDH1A1 275/4885 |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | NR2E1 344/4885CYP3A4 1111/4885ALDH1A1 175/4885 |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | NR2E1 1246/4885CYP3A4 73/4885ALDH1A1 275/4885 |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | CCNT1, CCNA1, CCND1 | NR2E1 1957/4885CYP3A4 688/4885ALDH1A1 860/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | NR2E1 1561/4885CYP3A4 1862/4885ALDH1A1 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.